Pembrolizumab, 5 mg

Pembrolizumab is a documented reagent, identified as an IgG4 monoclonal antibody. Its molecular formula is C267H383N445O119S4, with a molecular weight of approximately 149,259 g/mol. This compound belongs to the immunoglobulin superfamily, specifically targeting programmed death-1 (PD-1) proteins, thereby enhancing the immune system's response against cancer cells. It is supplied in a 5 mg form, making it suitable for various therapeutic applications in the treatment of advanced melanoma and non-small cell lung cancer. Additionally, Pembrolizumab has demonstrated high affinity and specificity towards PD-1, allowing for selective inhibition of tumor growth and promoting antitumor activity.

• CAS Number: 1374853-91-4